Skip to content
Cultural Foundation
Author:
VolitionRx Limited
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
September 17, 2026
VolitionRx Participates in Launch of DETECSEPS Program in France
September 17, 2026
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
September 14, 2026
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
September 10, 2026
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
August 12, 2026
Volition Advances Nu.Q® NETs Platform Towards Commercialization
July 30, 2026
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
July 7, 2026
VolitionRx Announces Collaboration with Sysmex
June 17, 2026